June 10, 2026 · 11 min read
GLP-1 obesity drugs are the largest new drug category in decades. Robotic surgery is penetrating less than 5% of eligible procedures. AI is compressing drug discovery timelines. Healthcare in 2026 is simultaneously defensive and one of the highest-growth sectors in the market.
AI scores use BriMindInvest's composite signal (20–96 scale). Operating margin shown for most recent reported fiscal year. Data June 2026.
| Ticker | Subsector | AI Score | Fwd P/E | Rev Growth | Gross Margin | Op Margin | Buy% | Target ↑ |
|---|---|---|---|---|---|---|---|---|
| LLY | Large-cap Pharma | 88 | 48x | +45% | 80% | 35% | 88% | +18% |
| ISRG | Robotic Surgery | 83 | 55x | +18% | 68% | 28% | 72% | +12% |
| NVO | Large-cap Pharma | 81 | 28x | +22% | 83% | 40% | 75% | +25% |
| ABBV | Immunology / Pharma | 79 | 15x | +14% | 70% | 32% | 72% | +15% |
| ABT | Diversified Med-Tech | 76 | 28x | +8% | 58% | 18% | 79% | +15% |
Gross margin above 60% is exceptional in pharma and med-tech — NVO (83%) and LLY (80%) lead, reflecting premium branded drug pricing power. The gap between gross margin and operating margin shows R&D and SG&A investment: LLY invests aggressively (35% op. margin vs. 80% gross) to sustain its GLP-1 pipeline lead.
Eli Lilly's tirzepatide franchise (Mounjaro for Type 2 diabetes, Zepbound for obesity) is the fastest-growing drug in pharma history. In Q1 2026, combined tirzepatide revenue exceeded $5B for a single quarter — an annualised $20B+ run rate from a drug approved just three years ago.
Pipeline optionality: Orforglipron (oral small-molecule GLP-1) eliminates the injection barrier that limits GLP-1 adoption. Phase 3 data showing 15.6% weight reduction at 36 weeks — superior to semaglutide — validates the oral route. An oral obesity drug addresses a market 3–5x larger than injectable GLP-1 (most obese people will not self-inject). Donanemab (Alzheimer's) adds a second potential $10B+ franchise.
Manufacturing as the key constraint: Lilly has committed $23B to manufacturing capacity expansion through 2028 — two new US facilities specifically for GLP-1 fill-finish operations. Until capacity scales, demand exceeds supply in several markets. This is a high-class problem, but it explains why sequential revenue growth has been supply-constrained rather than demand-constrained.
ISRG: Near-monopoly in soft-tissue robotic surgery with da Vinci 5 now shipping with AI surgical guidance. Razor-and-blades model generates $4B+/year in instruments/accessories — the recurring revenue stream that makes the 55x forward P/E more defensible than it looks.
NVO: Cheapest forward P/E (28x) of the major GLP-1 players. CagriSema at 25mg dose showed 22.7% weight reduction — re-rating from the initial Phase 2 disappointment. The oral semaglutide programme is a potential $15B+ product. Trades at a significant discount to LLY despite comparable gross margins.
ABBV: Best value in large-cap pharma at 15x forward earnings. Skyrizi+Rinvoq passing Humira peak revenue is the key catalyst that has already partially played out — but is not fully reflected in the multiple. 4th Skyrizi indication (UC) approved in 2026. Dividend yield of ~3.5% provides income while you wait for multiple re-rating.
ABT: Abbott's CGM franchise (FreeStyle Libre 4) is expanding beyond diabetes into metabolic health — a multi-billion opportunity. Most diversified of the group, with medical devices, diagnostics, and pharmaceuticals providing earnings stability. Best suited for investors wanting healthcare growth with lower concentration risk.
Free AI scores, pipeline data, operating margins, and analyst targets for any two healthcare stocks.